Join us on BioTech Health X as we sit down with Dr. Linda Marbán, CEO, and AJ Bergmann, CFO, of Capricor Therapeutics (NASDAQ: CAPR). This in-depth conversation sheds light on their groundbreaking work in developing cell and exosome-based therapies for rare diseases, with a focus on advancing transformative solutions for patients in need.
Key Highlights from the Interview
Deramiocel (CAP-1002): A Game-Changer for DMD
Capricor’s lead candidate, deramiocel, is an allogeneic cardiac-derived cell therapy that has shown promising results in treating Duchenne muscular dystrophy (DMD). Deramiocel’s immunomodulatory, antifibrotic, and regenerative properties target dystrophinopathies, offering hope to patients facing this devastating condition. Dr. Marbán shares insights into the therapy’s mechanism of action and its potential to redefine care for DMD.
Phase 3 Clinical Trials and FDA Meeting
The interview provides the latest updates on deramiocel’s Phase 3 clinical development, which is crucial for its path toward commercialization. Dr. Marbán and Mr. Bergmann also discuss the significance of the upcoming Pre-BLA (Biologics License Application) meeting with the FDA, a key milestone in Capricor’s journey to bring this therapy to market.
StealthX™ Platform: Unlocking the Potential of Exosome Technology
Capricor’s proprietary StealthX™ platform is paving the way for innovative treatments across a range of diseases. By harnessing exosomes for the targeted delivery of therapeutic payloads—such as oligonucleotides, proteins, and small molecules—the platform holds promise for addressing diverse medical challenges, from vaccinology to rare genetic disorders. Mr. Bergmann explains how Capricor’s exosome technology is shaping the future of precision medicine.
Russell 2000® Index Inclusion
Capricor’s inclusion in the Russell 2000® Index marks a significant achievement, highlighting the company’s growth and increasing recognition in the biotechnology sector. Dr. Marbán and Mr. Bergmann elaborate on what this milestone means for Capricor’s visibility and investor confidence.
Future Outlook: Transforming the Treatment Landscape
Looking ahead, Dr. Marbán and Mr. Bergmann share their vision for Capricor’s future. With a steadfast commitment to advancing cell and exosome-based therapies, the company aims to push the boundaries of possibility and bring life-changing treatments to patients battling rare and challenging diseases.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to redefining the treatment landscape for rare diseases through innovative cell and exosome-based therapeutics.
At the forefront of Capricor’s innovation is deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy currently in Phase 3 clinical development for Duchenne muscular dystrophy (DMD). Extensive preclinical and clinical studies have demonstrated its immunomodulatory, antifibrotic, and regenerative actions, offering a targeted approach to treating dystrophinopathies and heart disease.
Capricor is also leveraging its proprietary StealthX™ platform to develop exosome-based therapeutics. By focusing on the targeted delivery of therapeutic agents, the company aims to address a wide array of unmet medical needs, from rare genetic disorders to novel vaccine development.
Capricor remains committed to pioneering transformative treatments and improving the lives of patients worldwide.
Watch the Full Interview
Don’t miss this insightful conversation with Dr. Linda Marbán and AJ Bergmann as they discuss Capricor’s groundbreaking therapies and vision for the future. Click here to watch the full interview and stay informed on the latest advancements in biotechnology.
Subscribe to BioTech Health X for more exclusive interviews and updates from the forefront of biotech innovation.
